Labcorp and NOWDx Collaborate to Expand Access to Rapid Syphilis Testing

Original from: Labcorp

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today a new initiative with NOWDiagnostics (NOWDx), a leader in developing over-the-counter (OTC) and point-of-care (POC) diagnostic tests, to expand access to rapid syphilis testing. The companies will distribute First to Know® Syphilis Test kits at no cost to select community-based public health organizations across the country.

Syphilis is a sexually transmitted bacterial infection that is surging in the U.S., with over 209,000 reported cases in 2023 – the highest since 1950. Alarmingly, 60% of infected individuals are unaware they have syphilis due to often asymptomatic infections. Early detection is crucial, as untreated syphilis can cause severe damage to the eyes, heart, brain and other organs.

“Labcorp is committed to improving health and improving lives through innovative solutions that address critical public health challenges,” said Dr. Brian Caveney, Labcorp's chief medical and scientific officer. “By teaming up with NOWDx and supporting frontline healthcare providers, we’re making it easier to get tested, get treated and help stop the spread of syphilis in local communities.”

The First to Know Syphilis Test is the only over-the-counter test for syphilis that provides accurate results in just 15 minutes. Labcorp serves as the exclusive commercial laboratory offering the First to Know Syphilis Test for healthcare providers across the U.S. and also offers the test directly to consumers through Labcorp OnDemand.

Labcorp and NOWDx worked to identify and distribute the syphilis kits to more than 15 organizations nationwide, including LGBTQ+ health centers, HIV/AIDS care providers and safety-net clinics.

“Our mission is to empower public health professionals with tools that can change the trajectory of disease in their communities,” said Robert Weigle, CEO of NOWDx. “With Labcorp’s reach and shared commitment to addressing public health issues, this donation places rapid testing directly into the hands of providers serving those most at risk.”

This initiative underscores Labcorp’s broader commitment to innovation and expanding access to sexual health and STI testing. In recent months, the company launched multiple self-collection solutions available at Labcorp patient service centers (PSCs) and participating provider offices to expand screening for high-impact infections—including chlamydia and gonorrhea (CT/NG), Mycoplasma genitalium (Mgen), Trichomonas vaginalis (Trich), and human papillomavirus (HPV). These offerings are designed to empower patients, reduce barriers to care, and help clinicians detect and treat infections earlier.

Source: Labcorp and NOWDx Collaborate to Expand Access to Rapid Syphilis Testing